Clozapine Use in Two Full-Term Pregnancies

Stoner, Steven C.; Sommi, Roger W.; Marken, Patricia A.; Anya, Innocent; Vaughn, J.H.

doi:10.4088/jcp.v58n0806f

Cited by 55 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased risk of neonatal seizures due to the accumulation of clozapine in fetus was also reported (Stoner et al, 1997). However, in pregnant women receiving lorazepam, the withdrawal of the drug may diminish the convulsion threshold in newborns.…”

Section: Discussionmentioning

confidence: 87%

Case Report: Clozapine use in two women with schizophrenia during pregnancy

Duran¹,

Uğur²,

Turan³

et al. 2007

J Psychopharmacol

View full text Add to dashboard Cite

Stabilized patients who receive clozapine may wish to have children; but studies on pregnant women receiving clozapine treatment are limited. In this study, we report on clozapine use during pregnancy in two women. The first woman (Case 1) had two deliveries while she was receiving clozapine treatment for schizophrenia. Both her deliveries were term, uncomplicated vaginal deliveries, and the clozapine dose was reduced throughout pregnancy. The second woman (Case 2) developed schizophrenia after her first child was born. She became pregnant after clozapine initiation. She delivered twins by term, uncomplicated vaginal delivery. In our cases, no specific risks for the mothers and their children can be attributed to the use of clozapine. Physicians must be aware of the changes in fertility induced by prolactin-sparing drugs. Mothers who receive clozapine treatment should not be advised to breastfeed their children.

show abstract

Section: Discussionmentioning

confidence: 87%

Case Report: Clozapine use in two women with schizophrenia during pregnancy

Duran¹,

Uğur²,

Turan³

et al. 2007

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…Animal investigations, where doses much higher than the maximum recommended dose in humans were used, failed to demonstrate any increased incidence of malformations. There are still few reports on human pregnancies (20 cases) in which exposure to clozapine has occurred (Lieberman and Safferman, 1992;Waldman and Safferman, 1993;Barnas et al, 1994;Stoner et al, 1997). Two of these 114 reports have described the use of clozapine throughout the first trimester.…”

Section: A Antipsychotic Drugsmentioning

confidence: 99%

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

2004

View full text Add to dashboard Cite

“…Phenothiazines, haloperidol, and clozapine have all been reported to produce birth defects [3][4][5][6]; however, other studies have not confirmed these findings [7,8]. Acute neonatal effects of in utero exposure to clozapine and haloperidol have been described, including convulsions [9], floppy-infant syndrome [10,11], and lower developmental scores [12]. Longer-lasting behavioral deficits in infants may include "jittery" infant syndrome, tremor, and movement disorders, which may persist for up to 6 months [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors

Donohoe¹,

Aamodt²,

Osborn³

et al. 2006

Pharmacological Research

View full text Add to dashboard Cite

Antipsychotic drugs may produce adverse effects during development in humans and rodents. However, the extent of these effects has not been systematically characterized nor have molecular mechanisms been identified. Consequently, we sought to evaluate the effects of an extensive panel of antipsychotic drugs in a model organism, C. elegans, whose development is well characterized, and which offers the possibility of identifying novel molecular targets. For these studies, animals were grown from hatching in the presence of vehicle (control) or antipsychotic drugs over a range of concentrations (20-160 μM) and growth was analyzed by measuring head-to-tail length at various intervals. First-generation antipsychotics (e.g., fluphenazine) generally slowed growth and maturation more than second-generation drugs such as quetiapine, and olanzapine. This is consistent with in vitro effects on human neuronal cell lines. Clozapine, a second-generation drug, produced similar growth deficits as haloperidol. Converging lines of evidence, including the failure to rescue growth with high concentrations of agonists, suggested that the drug-induced delay in development was not mediated by the major neurotransmitter receptors recognized by the antipsychotic drugs. Moreover, in serotonin-deficient tph-1 mutants, the drugs dramatically slowed development and led to larval arrest (including dauer formation), and neuronal abnormalities. Evaluation of alternative targets of the antipsychotics revealed a potential role for calmodulin and underscored the significance of Ca 2+ -calmodulin signaling in development. These findings suggest that antipsychotic drugs may interfere with normal developmental processes, and provide a tool for investigating the key signaling pathways involved.

show abstract

Clozapine Use in Two Full-Term Pregnancies

Cited by 55 publications

References 0 publications

Case Report: Clozapine use in two women with schizophrenia during pregnancy

Case Report: Clozapine use in two women with schizophrenia during pregnancy

Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects

Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors

Contact Info

Product

Resources

About